Lockheed Martin Investment Management Co. Sells 154,260 Shares of Johnson & Johnson $JNJ

Lockheed Martin Investment Management Co. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 90.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 16,950 shares of the company’s stock after selling 154,260 shares during the period. Lockheed Martin Investment Management Co.’s holdings in Johnson & Johnson were worth $4,487,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its position in Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after buying an additional 2,513,321 shares during the period. Deutsche Bank AG lifted its holdings in shares of Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after buying an additional 1,225,676 shares during the last quarter. Amundi boosted its position in shares of Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares during the period. Janus Henderson Group PLC boosted its position in shares of Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after acquiring an additional 148,497 shares during the period. Finally, Jupiter Topco LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth $1,967,399,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company boosted their target price on shares of Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Citigroup increased their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a report on Monday, October 5th. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 15th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. Finally, Johnson Rice downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Johnson & Johnson Stock Up 2.0%

Shares of JNJ stock opened at $281.86 on Tuesday. The stock has a market cap of $678.53 billion, a P/E ratio of 42.71, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. Johnson & Johnson has a one year low of $185.12 and a one year high of $282.73. The stock has a fifty day moving average price of $266.18 and a 200 day moving average price of $248.62. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the previous year, the firm posted $2.80 EPS. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is 81.21%.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.